Hereditary pancreatic cancer [12 genes]
10-15% of pancreatic cancer are due to a predisposition syndrome towards hereditary cancer, such as hereditary breast and ovarian cancer, familial melanoma, Lynch syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome, or Li-Fraumeni syndrome. The remaining 85-90% do not present a recognizable genetic syndrome and are considered as familial pancreatic cancer (FPC). The recommended genetic study strategy is, therefore, to carry out a differential diagnosis of the main syndromes by sequencing genes like BRCA1, BRCA2, PALB2, CDKN2A, MLH1, MSH2, MSH6, APC, STK11, and TP53, among others.
Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.